InvestSMART

Oneview Healthcare Plc (ASX:ONE)

ALERT: Price-sensitive ASX Announcement for ONE
Current share price for ONE : $0.120 -0.05 (-29.41%)+
Announcement
Release
27 Aug 2026 9:06AM
Price at Release
$0.170
Full Release
download
Summary
Oneview Healthcare Plc’s Half Year 2026 Investor Presentation outlines H1 2026 progress toward scalable growth, with recurring revenue rising 13% year on year to €4.3 million, or 20% on a constant currency basis, while total revenue fell 14% to €5.5 million due to lower non-recurring revenue; gross margin improved materially to 70% from 61%, gross profit held at €3.8 million, cash operating expenses fell 6% to €7.8 million, operating EBITDA loss improved 11% to €4.0 million, and operating cash outflow reduced 15% to €4.1 million. The company ended 30 June 2026 with €7.2 million cash, or €11.4 million pro forma including the second tranche of its A$19 million placement. Commercially, Oneview reported four new logos in contract negotiation, 15,092 live endpoints, growth in the Baxter-sourced pipeline to 131 open opportunities representing 36,375 licensed beds, and a newly launched Bedside Hub product certified by Epic in May 2026 that has created a lower-cost entry channel into Epic health systems, with 16 active EpicTV opportunities representing 19,860 licensed beds and initial pilots due from September. Product development centred on a substantially complete new front end, expanded analytics, and Ovie’s evolution into an agentic intelligence layer for orchestrating patient and staff workflows, while AI-enabled engineering was said to improve development speed and bug investigation. The presentation also highlighted a pressured but stabilising Australia and New Zealand market, a US$50 billion US federal rural health transformation program aligned with Oneview’s capabilities, and H2 2026 priorities focused on converting late-stage deals, securing 3–4 new Bedside Hub customers, launching first deployments of the new front end and Bedside Hub, expanding within the installed base, and continuing progress toward cash flow breakeven.
Key Points
  • H1 2026 recurring revenue increased 13% to €4.3 million, while total revenue declined 14% to €5.5 million because of lower non-recurring revenue.
  • Gross margin rose to 70% from 61%, keeping gross profit flat at €3.8 million despite lower revenue.
  • Cash operating expenses fell 6% to €7.8 million and operating EBITDA loss improved 11% year on year to €4.0 million.
  • Net cash used in operating activities improved 15% to €4.1 million in H1 2026.
  • Cash at 30 June 2026 was €7.2 million, or €11.4 million pro forma including the second tranche of the A$19 million capital raising.
  • Bedside Hub was certified by Epic and launched in May 2026, opening a new revenue channel into Epic health systems.
  • Oneview had four new logos in contract negotiation across direct, Baxter and Epic Bedside Hub channels.
  • The company had 15,092 live endpoints at 30 June 2026, after deploying 693 endpoints and decommissioning 481 in the half.
  • Baxter’s open opportunity funnel comprised 131 opportunities representing 36,375 licensed beds, with 37 opportunities at design stage or beyond.
  • Since Epic certification, Oneview identified 16 active EpicTV opportunities representing 19,860 licensed beds, including reactivated previously stalled opportunities.
  • A 15-bed EpicTV pilot across three hospitals in a top 20 US health system was scheduled to begin in September 2026.
  • The new front end was substantially complete, with first deployments scheduled from September 2026.
  • Ovie is evolving into an agentic intelligence layer intended to automate and orchestrate patient and staff workflows.
  • The company said AI-enabled product development improved speed, with around 85% of code written by AI agents, 1.7 times faster feature development and about 5 times faster bug root-cause investigation.
  • In Australia and New Zealand, market conditions remained pressured but the active bid pipeline had increased from 3 in January to 8 by the presentation date.
  • H2 2026 priorities include converting late-stage opportunities, expanding within the installed base, targeting 3 to 4 new Bedside Hub wins and progressing toward cash flow breakeven.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.